Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study

BACKGROUND: This study aimed to investigate the preventive effects of tofogliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disease (CVD) by monitoring carotid intima-media thickn...

Descripción completa

Detalles Bibliográficos
Autores principales: Katakami, Naoto, Mita, Tomoya, Yoshii, Hidenori, Shiraiwa, Toshihiko, Yasuda, Tetsuyuki, Okada, Yosuke, Torimoto, Keiichi, Umayahara, Yutaka, Kaneto, Hideaki, Osonoi, Takeshi, Yamamoto, Tsunehiko, Kuribayashi, Nobuichi, Maeda, Kazuhisa, Yokoyama, Hiroki, Kosugi, Keisuke, Ohtoshi, Kentaro, Hayashi, Isao, Sumitani, Satoru, Tsugawa, Mamiko, Ryomoto, Kayoko, Taki, Hideki, Nakamura, Tadashi, Kawashima, Satoshi, Sato, Yasunori, Watada, Hirotaka, Shimomura, Iichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350187/
https://www.ncbi.nlm.nih.gov/pubmed/32646498
http://dx.doi.org/10.1186/s12933-020-01079-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350187/
https://www.ncbi.nlm.nih.gov/pubmed/32646498
http://dx.doi.org/10.1186/s12933-020-01079-4

Ejemplares similares